Gilead Data Suggest Role For ACC Inhibition In NASH
With Phase II data showing its ACC inhibitor GS-0976 can significantly reduce hepatic steatosis, Gilead moves a step closer to goal of developing a proprietary combo therapy for NASH.
With Phase II data showing its ACC inhibitor GS-0976 can significantly reduce hepatic steatosis, Gilead moves a step closer to goal of developing a proprietary combo therapy for NASH.